Displaying drugs 701 - 725 of 797 in total
ZYCOV-D
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India . The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest . Once the plasmid DNA is introduced into host cells and the viral protein is translated,...
Investigational
Matched Description: … As of August, 2020 the candidate is in Phase II clinical trials[A219758]. ... Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting ... successful dosing and tolerance[A219758,L16493]. …
CIGB-258 peptide
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the ... CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular …
Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe)
Experimental
Matched Name: … Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe) …
Matched Iupac: … 3-[20-(2-carboxyethyl)-15-ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo …
Matched Iupac: … 3-[20-(2-carboxyethyl)-15-ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo …
Anbenitamab
Investigational
Matched Synonyms: … FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific ... IgG1 antibody inhibiting PD-L1 and CTLA-4 …
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593]. ... Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge …
AMG 424
AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.
Investigational
Matched Synonyms: … Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38 …
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity ... In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known ... The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec …
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
BacTRL-spike
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
CVnCoV
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence ... and replication, to initiate subsequent immune responses in the body. ... The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration …
BNT162b3
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). ... Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate ... The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program …
ARGX-119
ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK).
Investigational
Matched Synonyms: … humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and …
Matched Description: … ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK). …
Matched Description: … ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK). …
TPX-4589
TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Investigational
Matched Synonyms: … Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload …
Matched Description: … TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and …
Matched Description: … TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence ... and replication, to initiate subsequent immune responses in the body. ... The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Viagenpumatucel-L
Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
Investigational
Matched Synonyms: … Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine …
TN-401
TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Investigational
Matched Synonyms: … A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type …
Matched Description: … TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and …
Matched Description: … TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and …
VOR33
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.
Investigational
Matched Synonyms: … allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking …
Matched Description: … VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy …
Matched Description: … VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy …
MVC-COV1901
MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as ISS-1018), for use with its vaccine. As of...
Investigational
Matched Description: … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity ... MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation …
Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)
The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells . This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. As...
Investigational
Matched Description: … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 ... Yunan Center for Disease Control and Prevention. ... SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and …
Pacanalotamab
Investigational
Matched Synonyms: … engager antibody with a single chain fc moiety that binds to b cell maturation antigen surface receptor and …
Ergidina
Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.
Investigational
Matched Synonyms: … Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1 and the cyclic …
Atacicept
Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
Investigational
Matched Synonyms: … Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein ( …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Cotsiranib
Investigational
Matched Synonyms: … interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and …
Dendritic cells vaccine
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation.
As...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials ... With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the ... The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and …
AG0301-COVID19
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Matched Description: … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of ... AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. ... The gene transfer method increases the efficiency of gene expression and antibody production capability …
Displaying drugs 701 - 725 of 797 in total